Jodi Rintelman writes her debut elf blog on the first randomised controlled trial on the efficacy and safety of intranasal esketamine as an adjunctive treatment to antidepressants for treatment-resistant depression.
[read the full story...]Jodi Rintelman writes her debut elf blog on the first randomised controlled trial on the efficacy and safety of intranasal esketamine as an adjunctive treatment to antidepressants for treatment-resistant depression.
[read the full story...]